Business Description
Trinity Biotech PLC
NAICS : 325413
SIC : 2835
ISIN : US8964383066
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.09 | |||||
Equity-to-Asset | -0.28 | |||||
Debt-to-Equity | -3.83 | |||||
Debt-to-EBITDA | -2.54 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.58 | |||||
Beneish M-Score | -3.52 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -14.5 | |||||
3-Year EBITDA Growth Rate | 16.7 | |||||
3-Year EPS without NRI Growth Rate | -29.1 | |||||
3-Year FCF Growth Rate | 6.8 | |||||
Future 3-5Y EPS without NRI Growth Rate | 15 | |||||
Future 3-5Y Total Revenue Growth Rate | -7.87 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 46.27 | |||||
9-Day RSI | 40.63 | |||||
14-Day RSI | 39.49 | |||||
6-1 Month Momentum % | -9.97 | |||||
12-1 Month Momentum % | -51.87 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.44 | |||||
Quick Ratio | 1.8 | |||||
Cash Ratio | 0.49 | |||||
Days Inventory | 174.9 | |||||
Days Sales Outstanding | 74.08 | |||||
Days Payable | 89.39 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.2 | |||||
Shareholder Yield % | 16.42 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 35.07 | |||||
Operating Margin % | -20.99 | |||||
Net Margin % | -40.06 | |||||
FCF Margin % | -18.1 | |||||
ROA % | -34.31 | |||||
ROIC % | -23.93 | |||||
ROC (Joel Greenblatt) % | -90.83 | |||||
ROCE % | -41.53 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.2 | |||||
EV-to-EBIT | -2.65 | |||||
EV-to-EBITDA | -2.85 | |||||
EV-to-Revenue | 1.05 | |||||
EV-to-Forward-Revenue | 1.11 | |||||
EV-to-FCF | -5.81 | |||||
Price-to-Median-PS-Value | 0.17 | |||||
Earnings Yield (Greenblatt) % | -37.74 | |||||
FCF Yield % | -93.64 | |||||
Forward Rate of Return (Yacktman) % | -121.06 |